MX347765B - Inhibidores macrociclicos de la quinasa flt3. - Google Patents

Inhibidores macrociclicos de la quinasa flt3.

Info

Publication number
MX347765B
MX347765B MX2014003807A MX2014003807A MX347765B MX 347765 B MX347765 B MX 347765B MX 2014003807 A MX2014003807 A MX 2014003807A MX 2014003807 A MX2014003807 A MX 2014003807A MX 347765 B MX347765 B MX 347765B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
macrocyclic
flt3 kinase
compounds
inhibitors
Prior art date
Application number
MX2014003807A
Other languages
English (en)
Other versions
MX2014003807A (es
Inventor
Marcella Françoise Blom Petra
Marie Cyriel Jozef Hoflack Jan
Original Assignee
Oncodesign Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncodesign Sa filed Critical Oncodesign Sa
Publication of MX2014003807A publication Critical patent/MX2014003807A/es
Publication of MX347765B publication Critical patent/MX347765B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos macrocíclicos y a composiciones que contienen esos compuestos, que actúan como inhibidores de quinasa, en particular, como inhibidores de FLT3 (tirosina quinasa 3, relacionada con FMS). Además, la presente invención provee procesos para la preparación de los compuestos descritos, así como métodos para usarlos, por ejemplo, como medicina; en particular para el tratamiento de trastornos de proliferación de células, tales como cáncer.
MX2014003807A 2011-09-30 2012-09-28 Inhibidores macrociclicos de la quinasa flt3. MX347765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011067084 2011-09-30
PCT/EP2012/069252 WO2013045653A1 (en) 2011-09-30 2012-09-28 Macrocyclic flt3 kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2014003807A MX2014003807A (es) 2015-01-12
MX347765B true MX347765B (es) 2017-05-12

Family

ID=46980944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003807A MX347765B (es) 2011-09-30 2012-09-28 Inhibidores macrociclicos de la quinasa flt3.

Country Status (14)

Country Link
US (2) US9090630B2 (es)
JP (1) JP6046728B2 (es)
KR (1) KR20140078710A (es)
CN (1) CN103930427B (es)
AU (1) AU2012314376B2 (es)
BR (1) BR112014007622A2 (es)
CA (1) CA2849999A1 (es)
DK (1) DK2760867T3 (es)
EA (1) EA025881B1 (es)
ES (1) ES2569048T3 (es)
HK (1) HK1198764A1 (es)
HU (1) HUE027318T2 (es)
MX (1) MX347765B (es)
WO (1) WO2013045653A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140095477A (ko) * 2011-09-30 2014-08-01 입센 파마 에스.에이.에스 마크로시클릭 lrrk2 키나제 억제제
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2014140235A1 (en) * 2013-03-15 2014-09-18 Ipsen Pharma S.A.S. Macrocyclic lrrk2 kinase inhibitors
AU2014230125A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A. Macrocyclic salt-inducible kinase inhibitors
AU2014230111A1 (en) * 2013-03-15 2015-10-29 Oncodesign S.A Macrocyclic RIP2 kinase inhibitors
AU2014264973B2 (en) * 2013-05-06 2018-01-18 Merck Patent Gmbh Macrocycles as kinase inhibitors
DK3636649T3 (da) 2014-01-24 2024-05-21 Turning Point Therapeutics Inc Diarylmakrocykler som modulatorer af proteinkinaser
WO2015136073A1 (en) * 2014-03-14 2015-09-17 Oncodesign Sa Macrocyclic tgf-br2 kinase inhibitors
DK3172213T3 (da) * 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US20170224700A1 (en) 2014-08-08 2017-08-10 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
DK3194405T3 (en) * 2014-09-17 2019-04-15 Oncodesign Sa MACROCYCLIC LRRK2 KINase INHIBITORS
ES2763344T3 (es) * 2014-09-17 2020-05-28 Oncodesign Sa Inhibidores macrocíclicos de la cinasa RIP2
WO2016146651A1 (en) 2015-03-16 2016-09-22 Oncodesign Sa Macrocyclic activin-like receptor kinase inhibitors
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
EP3325488B1 (en) 2015-07-21 2020-06-24 Turning Point Therapeutics, Inc. Chiral diaryl macrocycle and use thereof in the treatment of cancer
RU2630958C2 (ru) * 2015-12-29 2017-09-15 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) Новые макроциклические соединения, содержащие природное 3,7-диазабицикло[3.3.1]нонановое ядро и способ их получения
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
EP3490564A4 (en) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. MACRO CYCLE Kinase Inhibitors
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN111163771B (zh) 2017-02-28 2023-07-14 通用医疗公司 嘧啶并嘧啶酮类作为sik抑制剂的用途
WO2019023417A1 (en) 2017-07-28 2019-01-31 Tp Therapeutics, Inc. MACROCYCLIC COMPOUNDS AND USES THEREOF
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
CN110950889B (zh) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 一种多靶点激酶抑制剂及其制备方法和用途
WO2021113339A1 (en) 2019-12-03 2021-06-10 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU679789B2 (en) 1993-10-01 1997-07-10 Astra Aktiebolag Process I
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
JPWO2004039782A1 (ja) 2002-10-29 2006-03-02 麒麟麦酒株式会社 Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
BRPI0617489A2 (pt) 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase
WO2008016665A2 (en) 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Imidazoacridine compounds for treating flt3 -mediated disorders
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
SG176461A1 (en) * 2006-11-06 2011-12-29 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
WO2009017795A1 (en) 2007-08-02 2009-02-05 Xanthus Pharmaceuticals, Inc. Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers
ES2494365T3 (es) 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
CN101239978A (zh) 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
ES2548135T3 (es) * 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
KR20140095477A (ko) * 2011-09-30 2014-08-01 입센 파마 에스.에이.에스 마크로시클릭 lrrk2 키나제 억제제

Also Published As

Publication number Publication date
MX2014003807A (es) 2015-01-12
CN103930427A (zh) 2014-07-16
EA025881B1 (ru) 2017-02-28
CN103930427B (zh) 2016-03-09
US9090630B2 (en) 2015-07-28
BR112014007622A2 (pt) 2017-04-04
ES2569048T3 (es) 2016-05-06
HUE027318T2 (en) 2016-10-28
CA2849999A1 (en) 2013-04-04
EA201490707A1 (ru) 2014-08-29
DK2760867T3 (en) 2016-04-11
KR20140078710A (ko) 2014-06-25
HK1198764A1 (zh) 2015-06-05
WO2013045653A1 (en) 2013-04-04
JP6046728B2 (ja) 2016-12-21
US20150283141A1 (en) 2015-10-08
US20140303159A1 (en) 2014-10-09
US9370519B2 (en) 2016-06-21
JP2014528398A (ja) 2014-10-27
AU2012314376B2 (en) 2017-04-06
AU2012314376A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
MX347765B (es) Inhibidores macrociclicos de la quinasa flt3.
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015502615B1 (en) Chemical compounds
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MY177344A (en) Compounds and their methods of use
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
NZ700928A (en) Dna-pk inhibitors
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX349004B (es) Nuevos compuestos.
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
MX340402B (es) Inhibidores triciclicos de cinasas.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
PH12015500813A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
MX2014011326A (es) Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.

Legal Events

Date Code Title Description
FG Grant or registration